Erythropoietin: When liability becomes asset in neurovascular repair

Journal of Clinical Investigation

Volumn 118, Issue 2, 2008, Pages 467-470

  Grant, Maria B ^a   Boulton, Michael E ^b   Ljubimov, Alexander V ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE COURSE; NEUROPHYSIOLOGICAL RECRUITMENT; NEUROPROTECTION; NEUROVASCULAR REPAIR; NEUROVASCULAR RETINAL INJURY; NONHUMAN; NOTE; PATHOLOGY; PHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; RETINA INJURY; RETINA NEOVASCULARIZATION; TISSUE REPAIR;

ANIMALS; ERYTHROID PROGENITOR CELLS; ERYTHROPOIETIN; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEUROPROTECTIVE AGENTS; RETINAL DISEASES;

EID: 38849205803     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34643     Document Type: Note

References (39)

1. Smith, L.E., et al. 1994. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35:101-111.
2. Chen, J., and Smith, L.E. 2007. Retinopathy of prematurity. Angiogenesis. 10:133-140.
3. Mino, R.P., et al. 2001. Adenosine receptor antagonists and retinal neovascularization in vivo. Invest. Ophthalmol. Vis. Sci. 42:3320-3324.
4. Kramerov, A.A., et al. 2006. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am. J. Pathol. 168:1722-1736.
5. Chen, J., Connor, K.M., Aderman, C.M., and Smith, L.E.H. 2008. Erythropoietin deficiency decreases vascular stability in mice. J. Clin. Invest. 118:526-533. doi:10.1172/JCI33813.
6. Prost, M. 1988. Experimental studies on the pathogenesis of retinopathy of prematurity. Br. J. Ophthalmol. 72:363-367.
7. Moss, S.E., Klein, R., and Klein, B.E. 1994. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 101:1061-1070.
8. Fu, Y., et al. 2007. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest. Ophthalmol. Vis. Sci. 48:5184-5190.
9. Ferrara, N., Damico, L., Shams, N., Lowman, H., and Kim, R. 2006. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 26:859-870.
10. Hardee, M.E., Arcasoy, M.O., Blackwell, K.L., Kirkpatrick, J.P., and Dewhirst, M.W. 2006. Erythropoietin biology in cancer. Clin. Cancer Res. 12:332-339.
11. Juul, S., and Felderhoff-Mueser, U. 2007. Epo and other hematopoietic factors. Semin. Fetal Neonatal Med. 12:250-258.
12. Wang, G.L., Jiang, B.H., Rue, E.A., and Semenza, G.L. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 92:5510-5514.
13. Ema, M., et al. 1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. U. S. A. 94:4273-4278.
14. Wang, G.L., and Semenza, G.L. 1993. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268:21513-21518.
15. Parganas, E., et al. 1998. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 93:385-395.
16. -/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 98:181-191.
17. Milano, M., and Collomp, R. 2005. Erythropoietin and neuroprotection: a therapeutic perspective. J. Oncol. Pharm. Pract. 11:145-149.
18. Jelkmann, W. 2007. Erythropoietin after a century of research: younger than ever. Eur. J. Haematol. 78:183-205.
19. Grimm, C., et al. 2005. Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. Semin. Cell Dev. Biol. 16:531-538.
20. Kilic, U., et al. 2005. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J. 19:249-251.
21. van der Meer, P., Voors, A.A., Lipsic, E., van Gilst, W.H., and van Veldhuisen, D.J. 2004. Erythropoietin in cardiovascular diseases. Eur. Heart J. 25:285-291.
22. Amann, K., et al. 2000. Capillary/myocyte mismatch in the heart in renal failure - a role for erythropoietin? Nephrol. Dial. Transplant. 15:964-969.
23. Urao, N., et al. 2006. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ. Res. 98:1405-1413.
24. Petit, R.D., Warburton, R.R., Ou, L.C., and Hill, N.S. 1995. Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia. J. Appl. Physiol. 79:229-235.
25. Walker, B.R., Resta, T.C., and Nelin, L.D. 2000. Nitric oxide-dependent pulmonary vasodilation in polycythemic rats. Am. J. Physiol. Heart Circ. Physiol. 279:H2382-H2389.
26. Bahlmann, F.H., et al. 2004. Erythropoietin regulates endothelial progenitor cells. Blood. 103:921-926.
27. Napoli, C., Maione, C., Schiano, C., Fiorito, C., and Ignarro, L.J. 2007. Bone marrow cell-mediated cardiovascular repair: potential of combined therapies. Trends Mol. Med. 13:278-286.
28. Ward, M.R., Stewart, D.J., and Kutryk, M.J. 2007. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives. Catheter Cardiovasc. Interv. 70:983-998.
29. Watanabe, D., et al. 2005. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353:782-792.
30. Junk, A.K., et al. 2002. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 99:10659-10664.
31. Semba, R.D., and Juul, S.E. 2002. Erythropoietin in human milk: physiology and role in infant health. J. Hum. Lact. 18:252-261.
32. Sola, A., Wen, T.C., Hamrick, S.E., and Ferriero, D.M. 2005. Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr. Res. 57:110R-117R.
33. Ehrenreich, H., et al. 2002. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8:495-505.
34. Halperin, D.S., et al. 1990. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J. Pediatr. 116:779-786.
35. Shannon, K.M., et al. 1991. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. J. Pediatr. 118:949-955.
36. Gumy-Pause, F., et al. 2005. Stepping up versus standard doses of erythropoietin in preterm infants: a randomized controlled trial. Pediatr. Hematol. Oncol. 22:667-678.
37. Bierer, R., Peceny, M.C., Hartenberger, C.H., and Ohls, R.K. 2006. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 118:e635-e640.
38. Soubasi, V., et al. 1995. Follow-up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. J. Pediatr. 127:291-297.
39. Newton, N.R., Leonard, C.H., Piecuch, R.E., and Phibbs, R.H. 1999. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J. Perinatol. 19:403-406.